Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 18;18(14):7629.
doi: 10.3390/ijerph18147629.

Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?

Annika Kasprzak  1 , Jennifer Kaivers  1 , Kathrin Nachtkamp  1 , Rainer Haas  1 , Guido Kobbe  1 , Norbert Gattermann  1 , Ulrich Germing  1
Affiliations
Review

Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?

Annika Kasprzak et al. Int J Environ Res Public Health. .

Abstract

The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to examine how guidelines influence patients' adherence to expert recommendations and how they ensure healthcare quality. To approach this question, we reviewed the most common guidelines for diagnosing and treating MDS in adult patients. Furthermore, we critically looked at quality indicators for everyday practice and studied adherence in an everyday outpatient setting. Finally, we also paid close attention to patient-reported outcome measures and studied how they are used as endpoints in clinical trials. We can conclude that the combination of evidence-based diagnostic tools, standardized treatment recommendations, and patient-centered shared decision making will eventually lead to a healthcare standard that will significantly improve outcomes in adult patients with MDS.

Keywords: guidelines; myelodysplastic syndromes; patient reported outcome; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overview of diagnostic tools for diagnosing MDS.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Neukirchen J., Schoonen W.M., Strupp C., Gattermann N., Aul C., Haas R., Germing U. Incidence and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registry. Leuk. Res. 2011;35:1591–1596. doi: 10.1016/j.leukres.2011.06.001. - DOI - PubMed
    1. Heins M.J., de Jong J.D., Spronk I., Ho V.K.Y., Brink M., Korevaar J.C. Adherence to cancer treatment guidelines: Influence of general and cancer-specific guideline characteristics. Eur. J. Public Health. 2017;27:616–620. doi: 10.1016/S0959-8049(17)30458-6. - DOI - PubMed
    1. Greenberg P.L., Stone R.M., Al-Kali A., Barta S.K., Bejar R., Bennett J.M., Carraway H., De Castro C.M., Deeg H.J., DeZern A.E., et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2017;15:60–87. doi: 10.6004/jnccn.2017.0007. - DOI - PubMed
    1. Malcovati L., Hellström-Lindberg E., Bowen D., Adès L., Cermak J., Del Cañizo C., Della Porta M.G., Fenaux P., Gattermann N., Germing U., et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European LeukemiaNet. Blood. 2013;122:2943–2964. doi: 10.1182/blood-2013-03-492884. - DOI - PMC - PubMed
    1. Fenaux P., Haase D., Santini V., Sanz G.F., Platzbecker U., Mey U. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2021;32:142–156. doi: 10.1016/j.annonc.2020.11.002. - DOI - PubMed